trending Market Intelligence /marketintelligence/en/news-insights/trending/gxmaurlpzbwmtm_vaogw6g2 content esgSubNav
In This List

Loxo Oncology cancer drug secures US FDA breakthrough status

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Loxo Oncology cancer drug secures US FDA breakthrough status

Loxo Oncology Inc. said the U.S. Food and Drug Administration granted breakthrough therapy designation to LOXO-292, a potential treatment for certain types of lung and thyroid cancers.

The designation is based on the results of an ongoing early stage clinical trial where the drug demonstrated tumor reduction in about 80% of the patients enrolled in the study.

Under the FDA's breakthrough therapy designation, the regulator expedites the development and review of drugs, which demonstrate substantial improvement over existing therapies to treat a serious or life-threatening disease or condition.

The Stamford, Conn.-based biopharmaceutical company intends to update its program regarding the long-term development of the therapy after regulatory feedback in 2019.

Loxo is currently focused on the development of LOXO-195 and larotrectinib with Bayer AG.